Vanderbilt Center for Antibody Therapeutics (VCAT) Archive — Page 11 of 13

Close-up of an Anopheles mosquito feeding on blood from human skin, with its proboscis inserted into the skin and its abdomen visibly engorged red.
July 9, 2015

Study could lead to vaccine for mosquito-borne dengue virus

Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus.

By Bill Snyder
A person in a black shirt and jeans sits curled up with their head lowered and hands covering their face in a blue-walled room; another person is partially visible at the left edge.
July 8, 2015

Vanderbilt researchers develop potential treatment to fight mosquito-borne chikungunya virus

In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States.

By Nancy Humphrey
HIV cell
May 21, 2015

‘Redesigned’ antibodies may control HIV: study

With the help of a computer program called “Rosetta,” researchers at Vanderbilt University have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody.

By Bill Snyder
May 15, 2015

VU lands $9 million NIH grant to design better flu vaccines

Vanderbilt University researchers have received a five-year, $9 million grant from the National Institutes of Health (NIH) to design more effective flu vaccines and novel antibody therapies.

By Bill Snyder
Two researchers in white lab coats work at a laboratory biosafety cabinet; the seated researcher wears purple gloves and handles a tray while the other observes.
April 8, 2015

VU joins national effort to speed Ebola therapy testing

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.

By Bill Snyder
Cluster of fruit bats hanging upside down, with several bats showing open mouths and teeth.
February 26, 2015

Studies show human antibodies can fight lethal Marburg virus

Researchers at Vanderbilt University, the University of Texas Medical Branch at Galveston and The Scripps Research Institute for the first time have shown how human antibodies can neutralize the Marburg virus, a close cousin to Ebola.

By Bill Snyder